People choosing an alternative to COVID vaccines have this option.

Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching

Cureus, Published January 15, 2022

Abstract

A citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent infection and mortality rates versus non-ivermectin users.

The study analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program, which was conducted between July 2020 and December 2020 in Itajaí, Brazil.

In the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day.

Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score-matched by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without the use of propensity score matching (PSM).

Results:

  • There was a 44 percent reduction in COVID-19 infection rate for the cohorts using ivermectin prophylactically (p < 0.0001).
  • The regular use of ivermectin led to a 68 percent reduction in COVID-19 mortality (p < 0.0001). When adjusted for residual variables, the reduction in mortality rate was 70 percent (p < 0.0001).
  • There was a 56 percent reduction in hospitalization rate among ivermectin users and non-users, respectively (p < 0.0001). After adjustment for residual variables, the reduction in hospitalization rate was 67 percent (p < 0.0001).

COVID Study Conclusions

In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.

Obviously, this is an important study and validates the anecdotal data from various African countries where ivermectin is given prophylactically and incidence of COVID is very low (knowing that there are lots of confounding variables such as age, weight, and vitamin D3 levels found in many of these countries).

The P values of this study are extraordinary and can not be discounted easily by mainstream media.

But clearly, the leftist mainstream media are not making these results major news stories. Use your critical thinking to make personal decisions to protect your health.

Dr. Joel S. Hirschhorn, the author of Pandemic Blunder and many articles on the pandemic, worked on health issues for decades. As a full professor at the University of Wisconsin, Madison, he directed a medical research program between the colleges of engineering and medicine. As a senior official at the Congressional Office of Technology Assessment and the National Governors Association, he directed major studies on health-related subjects; he testified at over 50 U.S. Senate and House hearings and authored hundreds of articles and op-ed articles in major newspapers. He has served as an executive volunteer at a major hospital for more than 10 years. He is a member of the Association of American Physicians and Surgeons and America’s Frontline Doctors.

Buy the book Pandemic Blunder at www.amazon.com